D
ADC Therapeutics SA
ADCT
$1.23
-$0.10-7.52%
D
Sell
1/6/2025Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 1/6/2025 due to an increase in the volatility index.
E
Sell
11/18/2024Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 11/18/2024 due to a decline in the growth index and volatility index. EBIT declined 22.46% from -$29.04M to -$35.56M, and earnings per share declined from -$0.3819 to -$0.4195.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 11/18/2024 due to a decline in the growth index and volatility index. EBIT declined 22.46% from -$29.04M to -$35.56M, and earnings per share declined from -$0.3819 to -$0.4195.
D
Sell
1/29/2024Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 1/29/2024 due to an increase in the volatility index, total return index and valuation index.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 1/29/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
3/14/2023Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and valuation index.
ADC Therapeutics SA (ADCT) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and valuation index.
E
Sell
2/8/2023Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index, total return index and volatility index.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index, total return index and volatility index.
D
Sell
11/10/2022Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 11/10/2022 due to a significant increase in the growth index, valuation index and solvency index. Total revenue increased 341.39% from $17.29M to $76.32M, operating cash flow increased 104.14% from -$53.01M to $2.2M, and EBIT increased 95.51% from -$69.41M to -$3.11M.
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 11/10/2022 due to a significant increase in the growth index, valuation index and solvency index. Total revenue increased 341.39% from $17.29M to $76.32M, operating cash flow increased 104.14% from -$53.01M to $2.2M, and EBIT increased 95.51% from -$69.41M to -$3.11M.
D
Sell
9/21/2022Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 9/21/2022 due to an increase in the valuation index, volatility index and total return index.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 9/21/2022 due to an increase in the valuation index, volatility index and total return index.
E
Sell
8/12/2022Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 8/12/2022 due to a substantial decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.2169 to -$0.837, EBIT declined 67.35% from -$40.36M to -$67.55M, and total revenue declined 62.81% from $46.5M to $17.29M.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 8/12/2022 due to a substantial decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.2169 to -$0.837, EBIT declined 67.35% from -$40.36M to -$67.55M, and total revenue declined 62.81% from $46.5M to $17.29M.
D
Sell
5/16/2022Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 5/16/2022 due to a noticeable increase in the growth index, valuation index and solvency index. Total revenue increased 173.36% from $17.01M to $46.5M, earnings per share increased from -$0.4477 to -$0.2169, and operating cash flow increased 45.02% from -$61.63M to -$33.88M.
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 5/16/2022 due to a noticeable increase in the growth index, valuation index and solvency index. Total revenue increased 173.36% from $17.01M to $46.5M, earnings per share increased from -$0.4477 to -$0.2169, and operating cash flow increased 45.02% from -$61.63M to -$33.88M.
D
Sell
5/5/2022Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 8.63% from -$57.79M to -$62.78M, and operating cash flow declined 5.19% from -$58.59M to -$61.63M.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 8.63% from -$57.79M to -$62.78M, and operating cash flow declined 5.19% from -$58.59M to -$61.63M.
D
Sell
3/15/2022Downgrade
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 3/15/2022 due to a noticeable decline in the total return index, volatility index and solvency index.
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 3/15/2022 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
11/9/2021Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
ADC Therapeutics SA (ADCT) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index.
E
Sell
11/8/2021Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index. Debt to equity increased from 0.38 to 1.67.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index. Debt to equity increased from 0.38 to 1.67.
D
Sell
11/3/2021Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index, volatility index and solvency index.
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index, volatility index and solvency index.
D
Sell
10/4/2021Downgrade
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 10/4/2021 due to a decline in the volatility index.
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 10/4/2021 due to a decline in the volatility index.
D
Sell
9/17/2021Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 9/17/2021 due to an increase in the total return index and volatility index.
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 9/17/2021 due to an increase in the total return index and volatility index.
D
Sell
8/5/2021Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 8/5/2021 due to an increase in the growth index and volatility index. EBIT increased 0.26% from -$70.67M to -$70.48M.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 8/5/2021 due to an increase in the growth index and volatility index. EBIT increased 0.26% from -$70.67M to -$70.48M.
E
Sell
8/3/2021Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 8/3/2021 due to a decline in the volatility index and total return index.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 8/3/2021 due to a decline in the volatility index and total return index.
D
Sell
7/14/2021Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 7/14/2021 due to an increase in the volatility index.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 7/14/2021 due to an increase in the volatility index.
E
Sell
6/28/2021Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 6/28/2021 due to a decline in the total return index and volatility index.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 6/28/2021 due to a decline in the total return index and volatility index.
D
Sell
5/7/2021Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 5/7/2021 due to an increase in the growth index. EBIT increased 9.15% from -$77.79M to -$70.67M, and earnings per share increased from -$0.729 to -$0.67.
ADC Therapeutics SA (ADCT) was upgraded to D- from E+ on 5/7/2021 due to an increase in the growth index. EBIT increased 9.15% from -$77.79M to -$70.67M, and earnings per share increased from -$0.729 to -$0.67.
E
Sell
4/6/2021Downgrade
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 4/6/2021 due to a noticeable decline in the total return index and volatility index.
ADC Therapeutics SA (ADCT) was downgraded to E+ from D- on 4/6/2021 due to a noticeable decline in the total return index and volatility index.
D
Sell
3/19/2021Downgrade
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 3/19/2021 due to a major decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.2867 to -$0.729, EBIT declined 48.37% from -$52.43M to -$77.79M, and the quick ratio declined from 15.18 to 10.9.
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 3/19/2021 due to a major decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.2867 to -$0.729, EBIT declined 48.37% from -$52.43M to -$77.79M, and the quick ratio declined from 15.18 to 10.9.
D
Sell
11/20/2020Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 11/20/2020 due to a large increase in the growth index. Earnings per share increased from -$2.0132 to -$0.2867.
ADC Therapeutics SA (ADCT) was upgraded to D from D- on 11/20/2020 due to a large increase in the growth index. Earnings per share increased from -$2.0132 to -$0.2867.
D
Sell
10/16/2020Downgrade
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 10/16/2020 due to a significant decline in the volatility index and total return index.
ADC Therapeutics SA (ADCT) was downgraded to D- from D on 10/16/2020 due to a significant decline in the volatility index and total return index.
D
Sell
8/21/2020Downgrade
ADC Therapeutics SA (ADCT) was downgraded to D from D+ on 8/21/2020 due to a decline in the growth index, valuation index and volatility index. Earnings per share declined from -$1.4856 to -$2.0132, and EBIT declined 1.2% from -$44.42M to -$44.95M.
ADC Therapeutics SA (ADCT) was downgraded to D from D+ on 8/21/2020 due to a decline in the growth index, valuation index and volatility index. Earnings per share declined from -$1.4856 to -$2.0132, and EBIT declined 1.2% from -$44.42M to -$44.95M.
D
Sell
8/17/2020Upgraded
ADC Therapeutics SA (ADCT) was upgraded to D+ from D on 8/17/2020 due to a large increase in the total return index, volatility index and valuation index.
ADC Therapeutics SA (ADCT) was upgraded to D+ from D on 8/17/2020 due to a large increase in the total return index, volatility index and valuation index.
D
Sell
8/10/2020None
ADC Therapeutics SA (ADCT) was downgraded to D from U on 08/10/2020.
ADC Therapeutics SA (ADCT) was downgraded to D from U on 08/10/2020.
NYSE
04/03/2025 4:00PM Eastern
Quotes delayed
